恆指午後曾隨A股倒升逾百點 美團及藥明康德反覆升逾3%-4%
人行「降準」0.5個百分點今天生效,料為市場提供長期流動性約1萬億元人民幣。滬指及深成今早曾分別續挫3.5%及4.6%,至2,635及7,683齊創近五年低喘定,半日跌1.8%-2.3%,下午曾分別倒升0.4%及1.4%,高見2,739及8,171,現報2,705及7,988,跌0.9%及0.8%。
標普全球香港1月PMI回落至49.9,重陷輕微收縮。恆指今早在新經濟股主導下低開196點或近1.3%報15,336獲承接,半日反覆續跌0.1%,下午曾倒升136點至15,669遇阻,現報15,549,升15點或0.1%,總成交額745億元。
藍籌股個別發展,藥明康德(02359.HK)及藥明生物(02269.HK)扭轉尋底頹勢,最高見48元及17.84元,現報46.55元及17.08元,回升4.2%及1.7%。國藥(01099.HK)及翰森(03692.HK)反覆回升1.5%及2.5%,報20.65元及11.66元。然而,中生製藥(01177.HK)續跌2.1%報2.79元。
內需股以安踏(02020.HK)、李寧(02331.HK)及美團(03690.HK)表現較好,股價反覆回升1.6%-3%,後者股價由今早所創約4年半低位61.1元,掉頭高見66.75元,現報65.2,倒升3.2%。
網易(09999.HK)、中芯(00981.HK)、東方海外(00316.HK)及長建(01038.HK)反覆升1%-2%,後者報48元。然而,舜宇(02382.HK)低見43.5元創約七年低,現報45.05元,續跌3.2%。
華潤萬象(01209.HK)、新世界(00017.HK)、龍湖(00960.HK)及遭中金降價的恆隆地產(00101.HK續跌逾2%-3%,後兩者報8.38元及8.80元,均回吐逾3.5%。此外,出口股申洲(02313.HK)及創科(00669.HK)跌1.8%-2.8%,報66.95元及83.65元。
金融股以友邦(01299.HK)及招行(03968.HK)表現較好,股價反覆回升1.3%及1.1%,報60.55元及27.85元。然而,中銀(02388.HK)及港交所(00388.HK)跌1.8%及1.5%,報18.24元及230元。(sz/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.